University of Sussex
Browse
1/1
2 files

The prevalence of onchocerciasis in Africa and Yemen, 2000–2018: a geospatial analysis

journal contribution
posted on 2023-06-07, 07:56 authored by Chris A Schmidt, Elizabeth A Cromwell, Elex Hill, Katie M Donkers, Megan F Schipp, Kimberly B Johnson, David M Pigott, Jaffar Abbas, Victor Adekanmbi, Olatunji O Adetokunboh, Kebede Kassaye, others
Background Onchocerciasis is a disease caused by infection with Onchocerca volvulus, which is transmitted to humans via the bite of several species of black fly, and is responsible for permanent blindness or vision loss, as well as severe skin disease. Predominantly endemic in parts of Africa and Yemen, preventive chemotherapy with mass drug administration of ivermectin is the primary intervention recommended for the elimination of its transmission. Methods A dataset of 18,116 geo-referenced prevalence survey datapoints was used to model annual 2000–2018 infection prevalence in Africa and Yemen. Using Bayesian model-based geostatistics, we generated spatially continuous estimates of all-age 2000–2018 onchocerciasis infection prevalence at the 5 × 5-km resolution as well as aggregations to the national level, along with corresponding estimates of the uncertainty in these predictions. Results As of 2018, the prevalence of onchocerciasis infection continues to be concentrated across central and western Africa, with the highest mean estimates at the national level in Ghana (12.2%, 95% uncertainty interval [UI] 5.0–22.7). Mean estimates exceed 5% infection prevalence at the national level for Cameroon, Central African Republic, Democratic Republic of the Congo (DRC), Guinea-Bissau, Sierra Leone, and South Sudan. Conclusions Our analysis suggests that onchocerciasis infection has declined over the last two decades throughout western and central Africa. Focal areas of Angola, Cameroon, the Democratic Republic of the Congo, Ethiopia, Ghana, Guinea, Mali, Nigeria, South Sudan, and Uganda continue to have mean microfiladermia prevalence estimates exceeding 25%. At and above this level, the continuation or initiation of mass drug administration with ivermectin is supported. If national programs aim to eliminate onchocerciasis infection, additional surveillance or supervision of areas of predicted high prevalence would be warranted to ensure sufficiently high coverage of program interventions.

History

Publication status

  • Published

File Version

  • Published version

Journal

BMC Medicine

ISSN

1741-7015

Publisher

Springer Science and Business Media LLC

Volume

20

Page range

1-12

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2022-09-09

First Open Access (FOA) Date

2022-09-09

First Compliant Deposit (FCD) Date

2022-09-08

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC